We are pleased to announce that our new website
is launched from today, May 31, 2019. In
order to achieve our goal, a new growth stage called as "GTS 3.0",
which has been initiated since 2018, we are making concerted effort as one team,
and as part of that, our website is also redesigned to convey our messages more
simply and clearly.
Since the company was founded spun out from
Hokkaido University in March 2001, we have been developing a hybrid business
system for the past 18 years, which pursues a high business growth with new biologics
business and regenerative medicine (cell therapy) business while stabilizing
the business foundation in the biosimilar business. Now our biosimilar business comes at the
steady growth stage with pipelines that will be launched in the early 2020’s, following
our first biosimilar product, Filgrastim BS, launched in 2013. And, in order to realize "GTS 3.0"
from now on, we will work on the research and development of new pharmaceuticals
and therapeutic solutions in new biologics and regenerative medicine (cell
therapy) businesses by leveraging know-how and expertise regarding biotechnology
acquired in the biosimilar business.
Declining birthrate and the aging
population become a serious social issue not only in Japan but also developed countries
in the world. Under this situation, we
would like to contribute to healthcare with the therapeutic treatment for realizing
the brighter future for children through our new biologics and regenerative
medicine (cell therapy) businesses. Unfortunately,
it is the fact that research and development for pediatric diseases have not
been active in this industry, and therefore, we think it truly important to
support those children and juvenile people to be able to live healthier and
higher quality of life. In “GTS 3.0”, we
will strive to fulfill innovative transformation and pursue much higher growth
to realize such vision.
We would appreciate your continued support!
Gene Techno Science
President ＆ CEO